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Background. It is estimated that 347 million people suffer from diabetes mellitus (DM), and almost 5 million are blind due to
diabetic retinopathy (DR). The progression of DR can be slowed down with early diagnosis and treatment. Therefore our aim
was to develop a novel automated method for DR screening. Methods. 52 patients with diabetes mellitus were enrolled into the
project. Of all patients, 39 had signs of DR. Digital retina images and tear fluid samples were taken from each eye. The results from
the tear fluid proteomics analysis and from digital microaneurysm (MA) detection on fundus images were used as the input of a
machine learning system. Results. MA detection method alone resulted in 0.84 sensitivity and 0.81 specificity. Using the proteomics
data for analysis 0.87 sensitivity and 0.68 specificity values were achieved. The combined data analysis integrated the features of
the proteomics data along with the number of detected MAs in the associated image and achieved sensitivity/specificity values of
0.93/0.78. Conclusions. As the two different types of data represent independent and complementary information on the outcome,
the combined model resulted in a reliable screening method that is comparable to the requirements of DR screening programs
applied in clinical routine.
1. Introduction
It is estimated that today more than 347 million people
suffer from diabetes mellitus (DM) globally [1]. Diabetic
retinopathy (DR), one of the most common complications of
DM, accounts for about 5%ofworld blindness; this represents
almost 5 million people in 2002. Approximately 80% of all
patients with DM duration of at least 10 years suffer from
some degree of DR [2]. During the development of DR,
patients may not notice changes of their vision and DRmight
be very advanced by the time patients have visual complaints
and experience visual loss eventually.
In order to detect DR in an early stage everyone with DM
should be subjected to comprehensive dilated eye exam at
least once a year [3]. In case of early diagnosis, the progression
of DR can be slowed down by appropriate systemic or local
therapy.
More than two-thirds of patients with DM live in devel-
oping countries such as India (32 million) and China (21
million) where the access to high quality health care system
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is not universal [4]. As a result of the high human resource
cost of the DR screening programs, developed countries are
also looking for more cost-effective and scalable alternatives
to alter the existing methods.
Involvement of human graders is currently universal and
the less automation is in the system the greater the costs
are. Where possible, the digital photography method is the
screeningmethod of choice [5], althoughmany countries rely
on traditional clinical examination.
Recent photographic methods employ digital images
evaluated by qualified personnel. Based on mydriatic 45∘
retinal photographs examined by trained staff, the sensitivity
for the detection of sight-threateningDRhas been reported to
range between 87 and 100% with specificities of 83–96% [6].
The expected values for DR screening program as specified
by the British Diabetic Association (Diabetes UK) are at least
80% sensitivity and 95% specificity [7, 8].
Quality control concerns and cost efficiency have brought
forward the need for regular and centralized DR screening in
several developed countries [9]. Digital images are captured
at healthcare facilities and evaluated at grading centers by
qualified personnel or ophthalmologists [10]. The process
performs with high accuracy; however, it may not be scalable
and sustainable in economically challenged countries as it
requires intensive technical competence [11].
To improve the cost-effectiveness of DR screening several
image processing based methods have been developed in the
last decade providing an alternative to first phase exami-
nations performed by human graders [12, 13]. In this case,
the role of human graders would be reduced to examine
true positive or ambiguous images as well as perform quality
control on images that were described as normal by the
software after the automated prescreening process [14].
The hallmark of DR is microaneurysms (MAs). As these
outpouches occur on small blood vessels, most of the image
processing based screening methods concentrate on the
detection of this type of lesion.The International Retinopathy
Online Challenge offers an opportunity to compare the
results of image processing based algorithms for DR identifi-
cation viaMAdetection, where a screening system developed
by our research group achieved the best outcome in 2010 [15].
The specificity and sensitivity values of the automated MA
detectors are close to those of human graders [16–18]. Despite
the promising initial results, the use of image processing
based methods is limited in the clinical routine, probably
because their sensitivity and specificity cannot be improved
further. Nevertheless automated image clarity assessment
has been used in some places prior to human grading, for
example, the Scottish Screening Programme [19].
In this study, in order to increase the sensitivity and
specificity values of the photographic screening method, we
used an MA detector combined with tear fluid proteomics
based methodologies in one single system. The rationale
behind this was to use two independent but complimentary
techniques.
Currently tear fluid proteomics based methods are not
used in the clinical routine either. Protein profile changes
in tear fluid under abnormal pathological and physiological
conditions, such as inflammatory diseases or wound healing,
have been verified by several studies [20].
While vitreous humour proteome changes are known to
be more specific [21], implementing vitreous humour pro-
teomics in daily clinical practice is nevertheless problematic
as it requires invasive method of sampling.
However, tear fluid sampling may be an efficiently stan-
dardizable noninvasive process. In our previous study, we
analyzed the alteration of tear protein concentrations inDR in
order to determine which proteins, as potential biomarkers,
are found in tear fluid in DR patients [22].
In a previous paper our research group published the
first attempt for using tear fluid proteomics multimarkers for
DR screening. We applied machine learning algorithms to
predict whether the given patients with DM suffer from DR
or not, based on the global proteomics pattern changes of
their tear fluid. In that study we concluded that, due to its low
sensitivity (74%) and specificity (48%) values, the proteomics
based screening method alone is not appropriate for clinical
application at its present format. However, in combination
with other methods, it is able to improve the performance of
a combined system [23].
2. Materials and Methods
In the study we developed three automated screening sys-
tems. The first used image processing based algorithms in
order to detect MAs in digital retina images. The second
was based on the evaluation of tear fluid protein multimark-
ers. The third system combined the above mentioned MA
detection and tear fluid proteomics analysis. Thereafter we
assessed the performance of all three methods. Our aim was
to develop an automated DR screening system that reaches
the sensitivity and specificity values of screening performed
by human graders. In this way, compared to our previous
work, this new method represents significant improvement.
2.1. Patient Examination. Altogether, 52 patients with DM
were recruited into the study (21 males; 65.2 years average
age; 16.4 years average duration of diabetes; 14 NIDDM)
from the Ophthalmology Outpatient Clinic of the University
of Debrecen. At the time of the patient examination all
the patients were under antidiabetic medication. Out of all
patients, 39 had signs of DR. 16 patients out of the 39 have
undergone one or more laser photocoagulation treatment.
In our study, we only involved the eyes of the patients of
which we could obtain complete tear fluid proteomics data
and clinically evaluable fundus photos. Out of the potential
104 eyes, 74 had corresponding tear fluid analysis and grad-
able digital retinal images. Although the remaining 30 eyes
were also examined clinically, either difficulties in tear fluid
sampling, for example, noncompliance, operated eye, and
keratoconjunctivitis (9 participants), or difficulties during
the digital retina photography, for example, hemorrhage,
angle-closure glaucoma, and cataract (21 participants) led to
no procurement of relevant corresponding information as
shown in Table 1.
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Table 1: Characteristics of the participants.
Total number of participants enrolled Eye examination
52 104
Non-DR DR Eyes included Eyes excluded
Proliferative Nonproliferative Tear fluid sampling Retina photography
13 15 24 74 9 21
DR was determined by first capturing and then grading
standard 7-field fundus images. The images were taken
by Megaplus Camera Model 1,6i/10 BIT Zeiss (Carl Zeiss
Ophthalmic System A6, Jena, Germany). All of these were
assessed by two independent ophthalmologists.
The collected tear fluid samples were obtained under
standardized conditions by a qualified assistant [24]. The
samples were acquired using glass capillaries directly before
the pupil dilatation from the lower tear meniscus (a horizon-
tal thickening of the precorneal tear film by the lowermargin)
at the lateral canthus and care was taken not to touch the
conjunctiva. The time of the sampling procedure was noted.
The secretion rate was calculated by dividing the collected
tear volume by the time of sample collection and was given
in 𝜇L/min. Samples used in this analysis had secretion rates
of 5–15 𝜇L/min.
2.2. Machine Learning. During the project data process-
ing was performed by using machine learning algorithms.
Machine learning is a subfield of artificial intelligence and
it deals with the question as to how to construct computer
programs that can learn from data. The core task of machine
learning is performing inference from new samples. In
supervised learning the goal is to predict the value of an
outcome measure based on a number of input measures.
Supervised learning takes a known set of input data (training
set) and known responses (labeled output) to the data and
seeks to build a predictor model that generates reasonable
predictions for the response to new data.
In our case, the input data come from proteomics exper-
iments and from image processing based method, while the
predicted outcomes concern whether the certain patient has
DR or not. The model makes predictions using new data to
classify patients according to their tear proteomics data and
digital retinal image gradings and forms a well-defined way
to allow prescreening activities.
In the scientific literature no report can be found about
the possibility and potential relevance of combining tear
fluid proteomics and image processing on DR screening; the
method proposed by this paper is unprecedented.
2.3. Microaneurysm Detector. The image data was processed
using an MA detector, based on the image processing tech-
niques (Figure 1) [25, 26]. In short, the green plane of the
image is shade corrected, by subtracting the median filtered
version of the image (using a 35 × 35 rectangle) from the
green component of each pixel value. On the shade corrected
image, a contrast limited histogram equalization (CLAHE)
is performed, which is used to enhance the contrast of the
image.
This was followed by a 3 × 3median filtering for smooth-
ing. The next step of the processing is a top hat transform by
morphological reconstruction [27]. Top hat transform is an
image processing method used for small feature extraction.
The reconstructed image is opened by a 10×10 disk shape
to detect only small circular objects, resulting in candidate
MAs. The center of the candidates is calculated and the
following features are extracted for each candidate: area,
rotational inertia, mean intensity in the morphologically
opened image, mean intensity in green plane, and standard
deviation of intensity in green plane.
The Gradient Boosting Machine (GBM) model was used
to classify candidates MAs based on the above features [28,
29].
The testing was done based on hand marked MAs of the
retina images.
2.4. Tear Fluid Proteomics Based Method. Immediately after
sampling, the samples were centrifuged (1800 rpm) for 8–
10 minutes and supernatants were deep-frozen at −80∘C and
were thawed only once for measurements.
Protein identification was done from the tear fluid of
each of the patients. Tear samples were examined using
nano-HPLC coupled ESI-MS/MSmass spectrometry protein
identification as described elsewhere [22, 30, 31].
2.5. Application of Machine Learning Methods. Machine
learning method provided the basis of our DR screening
procedure. We have used learning data sets in order to teach
the machine learning algorithms to predict the occurrence
of certain future events, using empirical data containing
incomplete information. In our case the learning datasets
were the proteomics profiles, the retinal images, and the
clinical diagnosis (DR/non DR) of the enrolled diabetes
patients with DM.
Three classifiers were trained on the datasets; the first
model was based on fundus image data alone, the second on
using proteomics data, and the final was the combinedmodel.
During the process we used the best performing machine
learning algorithms, Naive Bayes Classifier in the first and
GBM in the other two models. 10-fold cross-validation
(repeated 10 times) was used to assess the performance of this
classifier.
The fundus images were processed using theMAdetector
algorithm, and a threshold was chosen for a candidate to be
classified as MA. The count of MAs on an image found this




Figure 1:Microaneurysm detection. (a) Original retina image; (b) CLAHE contrast enhancement; (c)median filtering; (d) top-hat transform;
(e) raw MA candidates.
way was used as the only feature for detecting DR, in case of
the first model. In Table 2, our results are reported at image
level.
We have used naive Bayes classifier for this analysis.
In the secondmodel the global pattern of protein concen-
trations and its changes were described by the examination of
the concentrations of 34 different proteins.
For the combined data analysis our input data were
protein levels measured in tear fluid samples from patients
with diabetes, the number of detected MAs in the associated
images, and clinical data regarding their DR status.
As a next step, following the learning process, we intended
to assess the performance of the screening method. At this
phase only the protein levels and retinal images were entered
into the system without diagnosis. Our goal was to show that
themodel based on both types of data has better performance
than the models based on either the image data or the
proteomics data alone. Figure 2 shows the learning and the
assessment phases of the application of the machine learning
algorithm.
We used k-fold cross-validation method to evaluate the
classifier’s performance based on the three dataset setup. In k-
fold cross-validation the data is first partitioned into k equally
(or nearly equally) sized segments or folds [32].
Afterwards k iterations of training and validation are
performed.Within each iteration different subsets of the data
are kept for validation process while the remaining 𝑘− 1-fold
are used for learning. At the end of the cross-validation, the
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Table 2: Performance measures of the screening methods.
Screening method SENS SPC ACC PREC NPV 𝐹1 LRP LRN
Image processing Mean 0.84 0.81 0.84 0.94 0.63 0.89 4.42 0.20
SD 0.11 0.04 0.10 0.13 0.11 0.11 2.36 0.11
Proteomics Mean 0.87 0.68 0.82 0.89 0.63 0.88 2.72 0.19
SD 0.17 0.12 0.11 0.21 0.15 0.16 1.24 0.12
Combined method Mean 0.93 0.78 0.89 0.93 0.78 0.93 4.23 0.09
SD 0.18 0.19 0.15 0.23 0.22 0.18 1.32 0.07
Performance measures of the image processing based, the tear proteomics based, and the combined screening methods. SENS: sensitivity, SPC: specificity,
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Figure 2: Application of machine learning algorithm in the combined model. Learning phase (above): we randomly select a subpopulation
of the total patient group, called the training group, and then use the known clinical diagnosis to split the training group into a DR group
and a non-DR group. The clinical diagnosis, the number of MAs on the retina images, and the protein concentration values are the inputs
of the machine learning algorithm. The algorithms are able to tell which data patterns are the most characteristic for the DR and non-DR
groups. Assessment phase (below): in the following steps, we use the data from the validation group. The number of MAs and the protein
concentration values constitute the input of the algorithm, but we do not use the information from clinical diagnosis. The learning algorithm
compares the new data to the characteristic patterns that are known from the learning phase and will make its own decision (normal/DR) for
each patient as the output of the model. For the assessment of the performance of the model, we compare the output with the known clinical
diagnosis.
estimate is determined as the mean of the features of the k-
fold model where we used 10-fold cross-validation, repeated
10 times.
With this basic form of cross-validation we obtained
estimations for many performance indicators such as speci-
ficity, sensitivity, accuracy, and F-measure (harmonic mean
of precision and sensitivity as a single measure for the
performance of the model).
During the 10-fold cross-validation process, the content
of learning and validation datasets has been randomly cho-
sen. In certain cases, one eye of a person was assigned to the
validation and the other to the learning dataset. Considering
the relatively low number of participants enrolled in the
project, this setting may increase significantly the perfor-
mance of the image processing based method. Therefore, we
tried to exclude this potential bias from our experiments.
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When the software splits the total patient group into a
validation and training set, we exclude the eyes from the
training set whose pair was in the validation set.
2.6. Data Analysis: Software Tools. We used the Smart-
biobank datamanagement system for the collection of experi-
mental (proteomics) and clinical data (DR/Non-DR)with the
related retinal images [33]. During the data analysis process
the 𝑅 statistical framework and the following packages have
been used: “gbm”, “caret”, “stat”, and “e1071” [34]. The image
processing tasks were done using the Octave software [35].
3. Results and Discussion
In case of the first model MA-count was used as the only fea-
ture for detecting DR. MA detection method alone resulted
in 0.84 sensitivity and 0.81 specificity values.
Using the proteomics data for analysis 0.87 sensitivity and
0.68 specificity values were achieved by using GBMmodels.
The combined model resulted in a more powerful clas-
sifier, achieving 0.93 sensitivity and 0.78 specificity values,
as the two different types of data provide independent and
complementary aspects of the underlying information of the
outcome.
Data in Table 2 demonstrate that the MA detector alone
performs significantly better than the tear proteomics based
method. Regarding accuracy measurement, the combined
method exceeds both image processing and proteomics based
methods values. Specificity value of the MA detector slightly
outperforms the specificity of the combined method as well.
Nevertheless, taking everything into consideration, the use of
proteomics data definitely improves the performance of the
MAdetector; therefore the combined screeningmethod is the
best classifier out of the three.
Over the last decade, several studies have been published
on the application of image processing methods for DR
screening. These methods, despite their promising perfor-
mances, are only slowly being applied in clinical practice.
In parallel, our team published the first attempt of
using tear fluid proteomics based method for DR screening.
Although the conclusion of this work was that this method
alone is not accurate enough for clinical use [23], there is
a definite scope for the improvement of the performance
of proteomics based classifier. With improvements in tear
fluid analysis, this method might become clinically useful
with time, as it requires little equipment for obtaining the
sample making potential mass-screening of DR in hard-to-
reach areas viable.
In theory, the performance of a classifier might be
improved by using the combination of different predictor
models [36, 37]. Combined diagnostic approaches are also
used in the routine medical practice to improve the clinical
effectiveness of existing screening programs [38].
Although there are numerous screening methods pub-
lished to be comparable to human graders, there is a lack
of systems that have been validated on independent cohort
using internationally recognized DR standard. Abramoff and
his workgroup published a method using combined MA,
hemorrhage, cotton wool spots, and exudates detection on a
diabetes at risk cohort of 874 participants.They completed the
method with the detection of irregular lesions such as large
hemorrhages and neovascularization. The sensitivity of the
system was 96.8% (95% CI, 94.4%–99.3%) with 59.4% (95%
CI, 55.7%–63.0%) specificity. The relatively low sensitivity
value limits the usability of the system [39].
The automated grading method published by Goatman
and his colleagues intended to remove normal images from
the image database before manual grading, thus reducing the
manual workload. The combined method was based on the
detection of MA, blot hemorrhages, and exudates. According
to thewell-known tradeoff between sensitivity and specificity,
the 100% sensitivity is coupled with low specificity value.
Considering that the system is proposed to be a pre-
screening tool, the workload reduction, ranged from 26.4%
(MA/BH/EX, both fields) to 38.1% (MA only, macular field),
is remarkable [40].
As we mentioned earlier, tear fluid proteomics based
methods are not used in the clinical routine. In experimental
settings the tear fluid proteomics based screening methods,
because of the expensive MS/MS experiments, limit the
application of larger sample sizes that are used in image
processing based projects.
Protein biomarkers and the MAs on retinal images
represent different data sources and information on DR eye.
Our results of 0.93 sensitivity and 0.78 specificity values
are close to reach the threshold recommended for routine
clinical screening of 80% and 95%, respectively. Considering
the 9 eyes for tear fluid proteomics examination and the 21
eyes for which the image processing cannot be performed,
the clinical examination protocol should be improved in
the future. Our future aim is to decrease the number of
the protein biomarkers applied in the screening system
in order to replace the MS/MS method to a more cost-
effective rapid test. To keep the performance of the method
we use Principal Component Analysis (PCA) to select the
potential biomarkers with the highest predictive values. For
this lower number of protein marker we intend to define
a concentration threshold instead of using the absolute
values of the concentrations. With the achievement of this
objective we will be able to develop a rapid test that can be
performed together with the retina photography. Potentially
the protein rapid test can be performed at the diabetes
patient’s home using a kit provided by the family practitioner
or the screening center via mail.
4. Conclusion
Our findings suggest that the maximal performance of this
method has not been reached yet. Results can be improved
in three potential ways: (i) by optimizing the parameter
settings of both tear fluid proteomics and MA detector based
classifiers; (ii) by comparing and choosing the best classifier
available for the combined screening method; (iii) by fine
tuning the patient examination and lab diagnostic protocols.
Considering that we intend to develop a prescreening
method, in order to decrease the workload of the DR screen-
ing centers, with the maximization of our system sensitivity,
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in a subsequent study, the potential workload reduction also
could be assessed.
Both tear sampling and retina photography are nonin-
vasive methods and can be implemented at general practi-
tioner’s settings. For the assessment of cost-effectiveness of
themethod further analysis is needed.However, it is expected
in the future that the cost of human resources in clinical care
becomes higher, in parallel with a rapid decrease in the cost
of IT and laboratory technologies. In light of these changes
the combinedmethod of tear fluid proteomics and computer-
assisted image processing of digital retinal photographs may
provide a promising alternative in DR screening.
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